Jiangsu Hengrui Pharmaceuticals is a China-based innovative pharmaceutical company headquartered in Lianyungang, Jiangsu Province. Founded in 1970, Hengrui generated revenue of RMB 31.63 billion (~$4.45 billion) in FY2025 with approximately 30,000 employees across 12 manufacturing facilities and a 5,500+ person R&D organization.
Business Overview
Jiangsu Hengrui Pharmaceuticals has established itself as China's premier innovative pharmaceutical company, achieving a pivotal milestone in FY2025 where innovative drug sales surpassed generic product sales for the first time. Innovative drug revenue reached RMB 16.34 billion (58.34% of total drug sales), representing 26.09% year-on-year growth, driven by oncology products contributing RMB 13.24 billion and non-oncology innovative products contributing RMB 3.10 billion. The company's R&D expenditure of RMB 8.72 billion (27.58% of revenue) in FY2025 ranks among the most intensive in the global pharmaceutical industry, funding more than 400 clinical trials with over 22,000 patients enrolled across the company's pipeline of 100+ new molecular entities.
Hengrui's dual-listing strategy on both the Shanghai Stock Exchange (SSE:600276) and Hong Kong Stock Exchange (HKEX:1276) has provided robust access to capital, with a RMB 41 billion cash reserve funding aggressive pipeline development. The company's global partnership strategy has proven remarkably successful: since 2023, Hengrui has executed 12 out-licensing deals with total aggregate deal value exceeding $27 billion, including landmark agreements with Merck KGaA for HRS-1167 (PARP1 inhibitor) plus SHR-A1904 (Claudin18.2 ADC) and with Elevar Therapeutics for multiple oncology assets. These deals validate Hengrui's discovery and early development capabilities while providing non-dilutive funding for continued pipeline investment. The commercial organization of approximately 9,000 field force representatives provides deep market penetration across all 31 mainland Chinese provinces and across all hospital tiers, from major academic medical centers in tier-1 cities to county-level hospitals in lower-tier markets.
Key Strengths
• Pipeline Depth: With 100+ NMEs in clinical development and approximately 20 potential FIC/BIC candidates entering the clinic annually, Hengrui's originated pipeline ranks among the global top 2 by size, competing directly with multinational pharmaceutical companies in discovery productivity.
• R&D Investment Scale: RMB 8.72 billion in annual R&D expenditure (27.58% of revenue) funds a 5,500+ scientist organization operating across 10+ technology platforms including small molecules, monoclonal antibodies, ADCs, bispecifics, PROTACs, and nucleic acid therapies.
• ADC Platform Excellence: Hengrui has built one of China's most advanced ADC platforms with differentiated linker-payload technology, generating multiple high-value out-licensing deals including the Merck KGaA collaboration worth up to $1.4 billion in upfront and milestone payments.
• Financial Fortress: RMB 41 billion in cash reserves, combined with strong operational cash flow and milestone income from licensing deals, provides an extended runway for pipeline investment without dependence on equity capital markets.
• China Oncology Dominance: With 10 approved oncology indications across camrelizumab (PD-1) alone, Hengrui commands leading market share positions in China's fastest-growing therapeutic category while building a comprehensive oncology portfolio spanning chemotherapy, targeted therapy, immunotherapy, and ADCs.
Challenges & Outlook
Hengrui faces significant headwinds from China's centralized volume-based procurement (VBP) program, which continues to compress generic drug prices by 50-90% across successive bidding rounds. While the company's pivot toward innovative drugs has largely offset generic revenue erosion—innovative drug sales now exceed generic sales—the remaining established products portfolio remains exposed to future VBP rounds. The company's heavy reliance on China's domestic market for over 90% of product revenue represents a concentration risk, particularly given ongoing regulatory and pricing uncertainties in China's pharmaceutical sector. However, Hengrui's strategic path forward appears compelling: the deep pipeline of 100+ NMEs with approximately 20 potential FIC/BIC candidates entering the clinic annually is expected to generate 5-7 new innovative drug approvals per year through 2030, while global out-licensing deals provide both validation and non-dilutive capital. The GLP-1/GIP dual agonist HRS9531, if successful in Phase 3 obesity trials, could unlock a multi-billion-dollar global market opportunity through a licensing partner. We rate Hengrui Pharma 86/100 on the VerityRank scale, reflecting its dominant innovation position in China's pharmaceutical market balanced against geographic concentration and VBP exposure.
